14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AXNX vs SIBN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, SI-BONE, Inc. (SIBN) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas SIBN carries 53.5/100 (HOLD) at $23.73 (N/M Forward P/E, -7.6% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs SIBN. Trailing 12-month operating profitability (AXNX N/A vs SIBN -7.6%) and valuation multiples (AXNX N/M vs SIBN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $1.1B market capitalization and -7.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AXNX vs SIBN Key Questions & Quantitative Answers
As of Nov 20, 2026, SI-BONE, Inc. (SIBN) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas SIBN carries 53.5/100 (HOLD) at $23.73 (N/M Forward P/E, -7.6% operating margin). Technically, AXNX sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and SIBN sits in a Markup phase (RSI 57.6, BREAKOUT options structure).
SIBN leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SIBN at +14.5% YoY revenue growth and +0.0% YoY earnings growth on $221M TTM revenue (79.4% gross margin, -7.6% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $221M for SIBN. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SIBN.
SIBN screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SIBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (-1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus SIBN (-7.7% ROE) capital efficiency.
In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, SIBN carries 149.2% implied volatility (48th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (0.65β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.